Skip to main content
. 2016 Apr 19;11(4):e0153151. doi: 10.1371/journal.pone.0153151

Fig 2. General design of chronic weight loss studies.

Fig 2

Baseline body weight and body composition measurements were made during the period Day -18 to -13 (left Black Arrow). Treatment with GSK457 was begun on Day -8 or -7 (Green Arrow). Subcutaneous exendin-4 AlbudAb dosing began on Day 0 (Red Arrow) and ended on Day 28 for the DIO study (right Black Arrow) and on Day 14 for the db/db study (middle Black Arrow); final body composition measurements were also made on that day. Blood was collected on the following day for serum chemistry, HbA1c and hormone analyses, and tissues were collected for histopathology (Blue Arrows).